1. Home
  2. LTRN

as of 11-19-2026 3:19pm EST

$0.29
$0.07
-19.33%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Founded: 2013 Country:
United States
United States
Employees: N/A City: DALLAS
Market Cap: 10.0M IPO Year: 2020
Target Price: $17.50 AVG Volume (30 days): 166.9K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.08 EPS Growth: 18.65
52 Week Low/High: $0.36 - $4.34 Next Earning Date: 11-17-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -0.33 Index: N/A
Free Cash Flow: -15678695.0 FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 18, 2026 · 100% conf.

AI Prediction BUY

1D

+3.20%

$0.37

Act: -12.67%

5D

+17.28%

$0.42

20D

+11.36%

$0.40

Price: $0.36 Prob +5D: 100% AUC: 1.000
0001493152-26-052991

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

NEWS

RELEASE

Lantern Pharma Reports Third Quarter 2026

Financial Results and Provides Business Updates

November 18, 2026

First clinical site engaged for Phase 1b/2 trial in triple negative breast cancer; Taiwan Approvals Open Part 2 of Phase 2 HARMONIC™ Trial of LP-300 in L858R Never-Smoker NSCLC; Peer-Reviewed Publication of LP-184 Phase 1a Glioblastoma Data Supports Planned Phase 1b/2a Combination Trial with Spironolactone; Approximately $4.0 Million Registered Direct Offering Closed September 30, 2026; Leadership Transition with CFO David Margrave Appointed Interim Chief Executive Officer

●Financing: Closed a registered direct offering and concurrent private placement on September 30, 2026, for gross proceeds of approximately $4.0 million. Cash, cash equivalents, and marketable securities were approximately $7.6 million as of September 30, 2026.

●LP-184

(zirdafulven) – First Clinical Site Engaged for Phase 1b/2 trial in triple negative breast cancer: In November 2026, the first clinical trial site completed the core study start-up milestones required to commence the study and is now engaged to begin enrollment. The Phase 1b/2 trial will enroll patients with advanced or metastatic TNBC, especially those harboring homologous recombination (HR) deficiencies, a population with high unmet medical need, and for which LP-184 received Fast Track designation from the FDA.

●LP-300

– HARMONIC™ Part 2 opens in Taiwan and the U.S.: In September 2026, the Taiwan FDA approved the amended HARMONIC™ protocol and the lead Taiwan site received IRB approval; the site is open to accrual and screening patients. In the U.S., a central IRB has approved the amended protocol. Part 2 is a single-arm study enrolling never-smoker patients with the EGFR exon 21 L858R mutation, with LP-300 dosing extended from six to a maximum of eight cycles.

●LP-184

– peer-reviewed glioblastoma data: Phase 1a data in 16 patients with recurrent glioblastoma (GBM), published in the October 2026 issue of Cancer Research Communications, showed LP-184 was generally well tolerated and, together with preclinical and pharmacokinetic modeling data, provide the dosing basis for a planned Phase 1b/2a trial of LP-184 (STAR-001) plus spironolactone (NCT07431216) under an FDA-cleared IND.

●LP-184

– EMA-cleared Phase 1b/2 bladder cancer trial in Denmark: In July 2026, Lantern announced that the European Medicines Agency (EMA) cleared an investigator-initiated Phase 1b/2 trial of LP-184 in biomarker-selected advanced bladder cancer, to be conducted at Rigshospitalet in Copenhagen, Denmark’s national referral center for urologic cancers. The site is now open for enrollment and is prescreening patients.

●Proposed settlement: In November 2026, the Company reached an agreement in principle to settle claims asserted by a former part-time consultant. The Company has accrued $2.0 million, its best estimate of loss, as of September 30, 2026; the expense is included in third quarter 2026 general and administrative expenses. The proposed settlement is not yet finalized or effective.

●Operating Results: R&D expenses decreased approximately 36% year over year, to approximately $1.6 million for Q3 2026. Loss from operations for Q3 2026 was approximately $5.4 million, including the $2.0 million proposed settlement accrual; excluding the accrual, loss from operations was approximately $3.4 million.

●Leadership transition: On November 15, 2026, Panna Sharma resigned as President and Chief Executive Officer and as a member of the Board of Directors. Effective November 16, 2026, the Board appointed David Margrave, the Company’s Chief Financial Officer, as Interim Chief Executive Officer until a permanent Chief Executive Officer is appointed. The Board intends to promptly commence a search for a successor.

●Open Medicine AI: In July 2026 Lantern formed Open Medicine AI (“OMAI”) as a wholly-owned subsidiary to commercialize the multi-agentic AI co-scientist platform originally launched as withZeta.ai.

1

DALLAS—(BUSINESS

WIRE)— Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the third quarter ended September 30, 2026, and provided an update on its leadership, its portfolio of AI-driven drug candidates, and its AI platforms.

The third quarter of 2026 and the weeks that followed brought significant developments for Lantern. The Company closed a financing at the end of the quarter for gross proceeds of approximately $4.0 million. In November, the first clinical site was engaged to commence initial enrollment for a Phase 1b/2 trial in relapsed or refractory triple-negative breast cancer (“TNBC”). In September, Lantern received Taiwan regulatory a

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 14, 2026 · 100% conf.

AI Prediction BUY

1D

+3.21%

$2.73

Act: -1.89%

5D

+17.29%

$3.11

Act: -11.70%

20D

+11.37%

$2.95

Price: $2.65 Prob +5D: 100% AUC: 1.000
0001493152-26-037979

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for Biomarker-Selected Bladder Cancer Trial; LP-184 Development Positioned to Advance in Multiple Indications including Triple Negative Breast Cancer and Pediatric Brain Cancers

●Open Medicine AI (OMAI) established as a separate company with board-approved commercial licensing agreements executed, operating the multi-agentic AI co-scientist platform previously launched as withZeta.ai. OMAI is currently wholly owned by Lantern and intends to raise capital at the OMAI level. A dedicated OMAI informational call is planned for mid-September 2026 to detail the market opportunity, platform roadmap, and commercial model.

●LP-300

– HARMONIC™ benefit deepens with treatment duration in emerging dataset: Median progression-free survival of 8.9 months in EGFR exon 21 L858R patients who completed six cycles of LP-300 (n=9), compared with 8.4 months across the overall L858R cohort (n=16), and a hazard ratio of 0.37 (95% CI 0.15–0.89) favoring the L858R subgroup. A 77% clinical benefit rate and tumor reduction in more than 70% of evaluable patients, with durable responses beyond two years — and no clinically meaningful toxicity added beyond chemotherapy.

●Phase 2 protocol amendment FDA-reviewed with no objections to key proposed amendments: enrollment will now be concentrated on EGFR exon 21 L858R patients with a single-arm design, and maximum LP-300 treatment extended from six to eight cycles. Enrollment will continue at sites in the United States and Taiwan.

●EMA

clearance in bladder cancer for LP-184 (zirdafulven): an investigator-initiated Phase

1b/2 trial of zirdafulven at Rigshospitalet in Denmark, among the first studies to prospectively select patients using a dual biomarker strategy — PTGR1 overexpression combined with tumor DNA-damage repair deficiency.

●FDA

cleared triple-negative breast cancer (TNBC) clinical trial advancing toward initiation:

a planned Phase 1b/2 trial of LP-184 monotherapy in relapsed/refractory advanced or metastatic TNBC with homologous recombination deficiency.

●USPTO

Notice of Allowance received for claims covering a three-gene expression signature used

to select patients for treatment with LP-184 across four solid tumor indications.

●Financial Position: Cash, cash equivalents, and marketable securities of approximately $7.4 million as of June 30, 2026. Funding received in the second quarter consisted of approximately $4.4 million in gross proceeds from the registered direct offering that closed on May 14, 2026. Second quarter loss from operations decreased approximately 25% year over year, to approximately $3.5 million for Q2 2026.

●Conference call and webcast scheduled for Friday, August 14, 2026 at 9:00 a.m. ET.

Lantern Pharma (Nasdaq: LTRN)August 14, 2026

DALLAS–(BUSINESS

WIRE)– Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the second quarter ended June 30, 2026, and provided an update on its portfolio of AI-driven drug candidates and AI platforms.

The second quarter of 2026 marked continued execution of Lantern’s strategy to translate its AI platform into differentiated clinical, regulatory, intellectual property, and commercial milestones. Emerging data from the HARMONIC™ trial indicated that LP-300’s progression-free survival benefit deepens with longer treatment duration in patients with EGFR exon 21 L858R-mutations, while the FDA reviewed key protocol amendments without objection. The European Medicines Agency (EMA) cleared an investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) for biomarker-selected, advanced bladder cancer patients, and the U.S. Patent and Trademark Office issued a Notice of Allowance covering a three-gene patient-selection signature for LP-184. In August, Lantern established Open Medicine AI as a separate company and entered into board-approved commercial licensing agreements. Reflecting ongoing operating discipline, loss from operations declined approximately 25% year over year for the quarter.

“The emerging HARMONIC™ data point to a clear observation: L858R patients who stay on LP-300 longer do better,” said Panna Sharma, President and Chief Executive Officer of Lantern Pharma. “A signal that strengthens with time should shape trial design, and that is exactly what our amended protocol does — concentrate enrollment where the benefit is deepest and extend treatment from six cycles to eight. The FDA reviewed those

2026
Q1

Q1 2026 Earnings

8-K SELL

May 15, 2026 · 100% conf.

AI Prediction SELL

1D

-4.17%

$3.01

Act: -4.40%

5D

-11.57%

$2.78

Act: +11.06%

20D

-8.13%

$2.88

Price: $3.14 Prob +5D: 0% AUC: 1.000
0001493152-26-023758

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

NEWS

RELEASE

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million

●Q1 net loss reduced 27% year-over-year while progressing multiple precision oncology programs

●Commercial introduction of withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development

●Successful outcome from Type C meeting request with the FDA focused on the LP-300 HARMONIC™ Clinical Trial

●Pediatric brain cancer IND cleared by FDA for enrollment for Lantern Pharma subsidiary, Starlight Therapeutics

●Strategic plan to create an independent entity composed of withZeta.ai assets

●Financial Position: Cash, cash equivalents, and marketable securities were approximately $6.3 million as of March 31, 2026; together with an additional approximately $4.4 million in gross proceeds from the May 14, 2026 financing, the Company’s pro forma liquidity is expected to fund operations into the middle of the first quarter of 2027.

DALLAS—(BUSINESS

WIRE)— Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter ended March 31, 2026, and provided an update on its portfolio of AI-driven drug candidates and AI platforms.

The first quarter of 2026 was defined by capital-efficient execution across Lantern’s clinical and AI platform pipelines. The Company advanced multiple clinical-stage programs through meaningful regulatory and scientific milestones, including a successful outcome from an FDA Type C meeting interaction on the Phase 2 HARMONIC™ trial of LP-300 and IND clearance for the first pediatric CNS cancer program of wholly-owned subsidiary Starlight Therapeutics, while reducing research and development spend by 47% year-over-year. In parallel, Lantern moved its proprietary AI infrastructure from internal capability to external commercial product with the launch of withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development. The recent fundraise of up to $9.25 million (which includes the potential future exercise of warrants) further strengthens the Company’s balance sheet and supports continued advancement of both its clinical pipeline and its AI commercialization strategy.

“The first quarter of 2026 demonstrated the operating discipline and capital-efficient execution that we believe is differentiating Lantern from other clinical-stage and AI-driven oncology companies,” said Panna Sharma, President and CEO of Lantern Pharma. “We reduced our R&D spend by 47% year-over-year while simultaneously advancing multiple clinical programs through important regulatory milestones, achieving a successful outcome from our Type C meeting request with the FDA on the HARMONIC™ trial, and clearing the path for Starlight Therapeutics’ first pediatric brain cancer trial. This level of milestone delivery on a tightly disciplined budget reflects exactly what our AI-driven drug development model was designed to do — develop more programs, more quickly, and at a fraction of the historical cost of biopharma R&D.”

In addition to Lantern’s clinical pipeline advancements, the first quarter also marked a pivotal evolution in the commercialization of the Company’s AI assets. With the public launch of withZeta.ai and the continued global expansion of the RADR® platform through the Company’s initiation of an AI Center of Excellence in India, Lantern is now operating two distinct value-creation engines: a clinical-stage drug development business aimed at advancing therapies across solid tumors, blood cancers, and pediatric brain cancers; and an AI platform business addressing the multi-billion-dollar opportunity in AI-enabled drug discovery and rare cancer research. To accelerate value realization across both engines, the Company has announced a strategic plan to create an independent business entity composed of its withZeta.ai platform assets, intended to access dedicated funding sources and pursue valuation distinct from clinical drug development operations.

“withZeta.ai represents Lantern’s first agentic-based commercial AI product, and we believe it is positioned to capture a meaningful share of what we view as a $20 to $50 billion near-term market opportunity in AI-driven drug development,” continued Mr. Sharma. “Separating our withZeta.ai assets into an independent entity is intended to unlock dedicated funding, attract specialized talent, and allow inv

Share on Social Networks: